Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter?
Bogdanos
Dimitrios-Petrou
DP
Mieli-Vergani
Giorgina
G
Vergani
Diego
D
D000328:Adult; D000918:Antibody Specificity; D000998:Antiviral Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D002648:Child; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D000637:Transaminases / Q000378:metabolism*; D016896:Treatment Outcome
D000998:Antiviral Agents; D001323:Autoantibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C060729:anti-liver kidney microsome antibody; D011092:Polyethylene Glycols; D012254:Ribavirin; D000637:Transaminases; C417083:peginterferon alfa-2b